Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning.
Identifieur interne : 000415 ( PubMed/Curation ); précédent : 000414; suivant : 000416Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning.
Auteurs : Yoonji Kim [Corée du Sud] ; Hansaem Lee [Corée du Sud] ; Keunwan Park [Corée du Sud] ; Sora Park [Corée du Sud] ; Ju-Hyeon Lim [Corée du Sud] ; Min Kyung So [Corée du Sud] ; Hye-Min Woo [Corée du Sud] ; Hyemin Ko [Corée du Sud] ; Jeong-Min Lee [Corée du Sud] ; Sun Hee Lim [Corée du Sud] ; Byoung Joon Ko [Corée du Sud] ; Yeon-Su Park [Corée du Sud] ; So-Young Choi [Corée du Sud] ; Du Hyun Song [Corée du Sud] ; Joo-Yeon Lee [Corée du Sud] ; Sung Soon Kim [Corée du Sud] ; Dae Young Kim [Corée du Sud]Source :
- Antibodies (Basel, Switzerland) [ 2073-4468 ] ; 2019.
Abstract
Since its first report in the Middle East in 2012, the Middle East respiratory syndrome-coronavirus (MERS-CoV) has become a global concern due to the high morbidity and mortality of individuals infected with the virus. Although the majority of MERS-CoV cases have been reported in Saudi Arabia, the overall risk in areas outside the Middle East remains significant as inside Saudi Arabia. Additional pandemics of MERS-CoV are expected, and thus novel tools and reagents for therapy and diagnosis are urgently needed. Here, we used phage display to develop novel monoclonal antibodies (mAbs) that target MERS-CoV. A human Fab phage display library was panned against the S2 subunit of the MERS-CoV spike protein (MERS-S2P), yielding three unique Fabs (S2A3, S2A6, and S2D5). The Fabs had moderate apparent affinities (Half maximal effective concentration (EC50 = 123-421 nM) for MERS-S2P, showed no cross-reactivity to spike proteins from other CoVs, and were non-aggregating and thermostable (Tm = 61.5-80.4 °C). Reformatting the Fabs into IgGs (Immunoglobulin Gs) greatly increased their apparent affinities (KD = 0.17-1.2 nM), presumably due to the effects of avidity. These apparent affinities were notably higher than that of a previously reported anti-MERS-CoV S2 reference mAb (KD = 8.7 nM). Furthermore, two of the three mAbs (S2A3 and S2D5) bound only MERS-CoV (Erasmus Medical Center (EMC)) and not other CoVs, reflecting their high binding specificity. However, the mAbs lacked MERS-CoV neutralizing activity. Given their high affinity, specificity, and desirable stabilities, we anticipate that these anti-MERS-CoV mAbs would be suitable reagents for developing antibody-based diagnostics in laboratory or hospital settings for point-of-care testing.
DOI: 10.3390/antib8030042
PubMed: 31544848
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000415
Links to Exploration step
pubmed:31544848Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning.</title><author><name sortKey="Kim, Yoonji" sort="Kim, Yoonji" uniqKey="Kim Y" first="Yoonji" last="Kim">Yoonji Kim</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Lee, Hansaem" sort="Lee, Hansaem" uniqKey="Lee H" first="Hansaem" last="Lee">Hansaem Lee</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Park, Keunwan" sort="Park, Keunwan" uniqKey="Park K" first="Keunwan" last="Park">Keunwan Park</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Park, Sora" sort="Park, Sora" uniqKey="Park S" first="Sora" last="Park">Sora Park</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Lim, Ju Hyeon" sort="Lim, Ju Hyeon" uniqKey="Lim J" first="Ju-Hyeon" last="Lim">Ju-Hyeon Lim</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="So, Min Kyung" sort="So, Min Kyung" uniqKey="So M" first="Min Kyung" last="So">Min Kyung So</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Woo, Hye Min" sort="Woo, Hye Min" uniqKey="Woo H" first="Hye-Min" last="Woo">Hye-Min Woo</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Ko, Hyemin" sort="Ko, Hyemin" uniqKey="Ko H" first="Hyemin" last="Ko">Hyemin Ko</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Lee, Jeong Min" sort="Lee, Jeong Min" uniqKey="Lee J" first="Jeong-Min" last="Lee">Jeong-Min Lee</name><affiliation wicri:level="1"><nlm:affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813</wicri:regionArea></affiliation></author><author><name sortKey="Lim, Sun Hee" sort="Lim, Sun Hee" uniqKey="Lim S" first="Sun Hee" last="Lim">Sun Hee Lim</name><affiliation wicri:level="1"><nlm:affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813</wicri:regionArea></affiliation></author><author><name sortKey="Ko, Byoung Joon" sort="Ko, Byoung Joon" uniqKey="Ko B" first="Byoung Joon" last="Ko">Byoung Joon Ko</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Park, Yeon Su" sort="Park, Yeon Su" uniqKey="Park Y" first="Yeon-Su" last="Park">Yeon-Su Park</name><affiliation wicri:level="1"><nlm:affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813</wicri:regionArea></affiliation></author><author><name sortKey="Choi, So Young" sort="Choi, So Young" uniqKey="Choi S" first="So-Young" last="Choi">So-Young Choi</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Song, Du Hyun" sort="Song, Du Hyun" uniqKey="Song D" first="Du Hyun" last="Song">Du Hyun Song</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Lee, Joo Yeon" sort="Lee, Joo Yeon" uniqKey="Lee J" first="Joo-Yeon" last="Lee">Joo-Yeon Lee</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Sung Soon" sort="Kim, Sung Soon" uniqKey="Kim S" first="Sung Soon" last="Kim">Sung Soon Kim</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Dae Young" sort="Kim, Dae Young" uniqKey="Kim D" first="Dae Young" last="Kim">Dae Young Kim</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea. kimdae@kbiohealth.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31544848</idno><idno type="pmid">31544848</idno><idno type="doi">10.3390/antib8030042</idno><idno type="wicri:Area/PubMed/Corpus">000415</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000415</idno><idno type="wicri:Area/PubMed/Curation">000415</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000415</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning.</title><author><name sortKey="Kim, Yoonji" sort="Kim, Yoonji" uniqKey="Kim Y" first="Yoonji" last="Kim">Yoonji Kim</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Lee, Hansaem" sort="Lee, Hansaem" uniqKey="Lee H" first="Hansaem" last="Lee">Hansaem Lee</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Park, Keunwan" sort="Park, Keunwan" uniqKey="Park K" first="Keunwan" last="Park">Keunwan Park</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Park, Sora" sort="Park, Sora" uniqKey="Park S" first="Sora" last="Park">Sora Park</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Lim, Ju Hyeon" sort="Lim, Ju Hyeon" uniqKey="Lim J" first="Ju-Hyeon" last="Lim">Ju-Hyeon Lim</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="So, Min Kyung" sort="So, Min Kyung" uniqKey="So M" first="Min Kyung" last="So">Min Kyung So</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Woo, Hye Min" sort="Woo, Hye Min" uniqKey="Woo H" first="Hye-Min" last="Woo">Hye-Min Woo</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Ko, Hyemin" sort="Ko, Hyemin" uniqKey="Ko H" first="Hyemin" last="Ko">Hyemin Ko</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Lee, Jeong Min" sort="Lee, Jeong Min" uniqKey="Lee J" first="Jeong-Min" last="Lee">Jeong-Min Lee</name><affiliation wicri:level="1"><nlm:affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813</wicri:regionArea></affiliation></author><author><name sortKey="Lim, Sun Hee" sort="Lim, Sun Hee" uniqKey="Lim S" first="Sun Hee" last="Lim">Sun Hee Lim</name><affiliation wicri:level="1"><nlm:affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813</wicri:regionArea></affiliation></author><author><name sortKey="Ko, Byoung Joon" sort="Ko, Byoung Joon" uniqKey="Ko B" first="Byoung Joon" last="Ko">Byoung Joon Ko</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Park, Yeon Su" sort="Park, Yeon Su" uniqKey="Park Y" first="Yeon-Su" last="Park">Yeon-Su Park</name><affiliation wicri:level="1"><nlm:affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813</wicri:regionArea></affiliation></author><author><name sortKey="Choi, So Young" sort="Choi, So Young" uniqKey="Choi S" first="So-Young" last="Choi">So-Young Choi</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Song, Du Hyun" sort="Song, Du Hyun" uniqKey="Song D" first="Du Hyun" last="Song">Du Hyun Song</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author><author><name sortKey="Lee, Joo Yeon" sort="Lee, Joo Yeon" uniqKey="Lee J" first="Joo-Yeon" last="Lee">Joo-Yeon Lee</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Sung Soon" sort="Kim, Sung Soon" uniqKey="Kim S" first="Sung Soon" last="Kim">Sung Soon Kim</name><affiliation wicri:level="1"><nlm:affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Dae Young" sort="Kim, Dae Young" uniqKey="Kim D" first="Dae Young" last="Kim">Dae Young Kim</name><affiliation wicri:level="1"><nlm:affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea. kimdae@kbiohealth.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160</wicri:regionArea></affiliation></author></analytic><series><title level="j">Antibodies (Basel, Switzerland)</title><idno type="eISSN">2073-4468</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since its first report in the Middle East in 2012, the Middle East respiratory syndrome-coronavirus (MERS-CoV) has become a global concern due to the high morbidity and mortality of individuals infected with the virus. Although the majority of MERS-CoV cases have been reported in Saudi Arabia, the overall risk in areas outside the Middle East remains significant as inside Saudi Arabia. Additional pandemics of MERS-CoV are expected, and thus novel tools and reagents for therapy and diagnosis are urgently needed. Here, we used phage display to develop novel monoclonal antibodies (mAbs) that target MERS-CoV. A human Fab phage display library was panned against the S2 subunit of the MERS-CoV spike protein (MERS-S2P), yielding three unique Fabs (S2A3, S2A6, and S2D5). The Fabs had moderate apparent affinities (Half maximal effective concentration (<i>EC</i><sub>50</sub> = 123-421 nM) for MERS-S2P, showed no cross-reactivity to spike proteins from other CoVs, and were non-aggregating and thermostable (<i>T</i><sub>m</sub> = 61.5-80.4 °C). Reformatting the Fabs into IgGs (Immunoglobulin Gs) greatly increased their apparent affinities (<i>K</i><sub>D</sub> = 0.17-1.2 nM), presumably due to the effects of avidity. These apparent affinities were notably higher than that of a previously reported anti-MERS-CoV S2 reference mAb (<i>K</i><sub>D</sub> = 8.7 nM). Furthermore, two of the three mAbs (S2A3 and S2D5) bound only MERS-CoV (Erasmus Medical Center (EMC)) and not other CoVs, reflecting their high binding specificity. However, the mAbs lacked MERS-CoV neutralizing activity. Given their high affinity, specificity, and desirable stabilities, we anticipate that these anti-MERS-CoV mAbs would be suitable reagents for developing antibody-based diagnostics in laboratory or hospital settings for point-of-care testing.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31544848</PMID><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4468</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Antibodies (Basel, Switzerland)</Title><ISOAbbreviation>Antibodies (Basel)</ISOAbbreviation></Journal><ArticleTitle>Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">E42</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antib8030042</ELocationID><Abstract><AbstractText>Since its first report in the Middle East in 2012, the Middle East respiratory syndrome-coronavirus (MERS-CoV) has become a global concern due to the high morbidity and mortality of individuals infected with the virus. Although the majority of MERS-CoV cases have been reported in Saudi Arabia, the overall risk in areas outside the Middle East remains significant as inside Saudi Arabia. Additional pandemics of MERS-CoV are expected, and thus novel tools and reagents for therapy and diagnosis are urgently needed. Here, we used phage display to develop novel monoclonal antibodies (mAbs) that target MERS-CoV. A human Fab phage display library was panned against the S2 subunit of the MERS-CoV spike protein (MERS-S2P), yielding three unique Fabs (S2A3, S2A6, and S2D5). The Fabs had moderate apparent affinities (Half maximal effective concentration (<i>EC</i><sub>50</sub> = 123-421 nM) for MERS-S2P, showed no cross-reactivity to spike proteins from other CoVs, and were non-aggregating and thermostable (<i>T</i><sub>m</sub> = 61.5-80.4 °C). Reformatting the Fabs into IgGs (Immunoglobulin Gs) greatly increased their apparent affinities (<i>K</i><sub>D</sub> = 0.17-1.2 nM), presumably due to the effects of avidity. These apparent affinities were notably higher than that of a previously reported anti-MERS-CoV S2 reference mAb (<i>K</i><sub>D</sub> = 8.7 nM). Furthermore, two of the three mAbs (S2A3 and S2D5) bound only MERS-CoV (Erasmus Medical Center (EMC)) and not other CoVs, reflecting their high binding specificity. However, the mAbs lacked MERS-CoV neutralizing activity. Given their high affinity, specificity, and desirable stabilities, we anticipate that these anti-MERS-CoV mAbs would be suitable reagents for developing antibody-based diagnostics in laboratory or hospital settings for point-of-care testing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yoonji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hansaem</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Keunwan</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8783-9495</Identifier><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sora</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Ju-Hyeon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>So</LastName><ForeName>Min Kyung</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Hye-Min</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Hyemin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jeong-Min</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Sun Hee</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Byoung Joon</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yeon-Su</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Plexense, Inc., Yongin-si, Gyeonggi-do 441-813, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>So-Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Du Hyun</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joo-Yeon</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sung Soon</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Korea Center for Disease Control, Osong Health Technology Administration Complex, Cheongju-si, Chungcheongbuk-do 28159, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dae Young</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Chungcheongbuk-do 28160, Korea. kimdae@kbiohealth.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibodies (Basel)</MedlineTA><NlmUniqueID>101587489</NlmUniqueID><ISSNLinking>2073-4468</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">S2 subunit</Keyword><Keyword MajorTopicYN="N">monoclonal antibody</Keyword><Keyword MajorTopicYN="N">phage display</Keyword><Keyword MajorTopicYN="N">spike protein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31544848</ArticleId><ArticleId IdType="pii">antib8030042</ArticleId><ArticleId IdType="doi">10.3390/antib8030042</ArticleId><ArticleId IdType="pmc">PMC6783954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Apr;20(4):560-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24655427</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2010;627:91-100</Citation><ArticleIdList><ArticleId IdType="pubmed">20217615</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357</Citation><ArticleIdList><ArticleId IdType="pubmed">28807998</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2018 Apr 27;92(10):</Citation><ArticleIdList><ArticleId IdType="pubmed">29514901</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Jan;22(1):32-40</Citation><ArticleIdList><ArticleId IdType="pubmed">26692003</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Lab Med. 2016 May;36(3):230-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26915611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Front Microbiol. 2016 Apr 20;7:509</Citation><ArticleIdList><ArticleId IdType="pubmed">27148198</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2015 Nov;25(11):1237-49</Citation><ArticleIdList><ArticleId IdType="pubmed">26391698</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Microbiol. 2015 Apr;53(4):1178-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25631809</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Apr;20(4):552-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24655412</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2012 Dec 06;17(49):null</Citation><ArticleIdList><ArticleId IdType="pubmed">23231891</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2014 Apr 30;6(234):234ra59</Citation><ArticleIdList><ArticleId IdType="pubmed">24778414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2015 May;15(5):559-64</Citation><ArticleIdList><ArticleId IdType="pubmed">25863564</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2015 Nov;21(11):2029-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26488195</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Virol. 2016 Sep 29;3(1):237-261</Citation><ArticleIdList><ArticleId IdType="pubmed">27578435</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Microbes Infect. 2015 Apr;4(4):e26</Citation><ArticleIdList><ArticleId IdType="pubmed">26421268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2016 Jan 20;11(1):e0146251</Citation><ArticleIdList><ArticleId IdType="pubmed">26790002</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MBio. 2016 Mar 01;7(2):e00019</Citation><ArticleIdList><ArticleId IdType="pubmed">26933050</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation><ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2013 Feb 21;18(8):null</Citation><ArticleIdList><ArticleId IdType="pubmed">23449231</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Genome Announc. 2018 Mar 22;6(12):null</Citation><ArticleIdList><ArticleId IdType="pubmed">29567734</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2014 Dec 19;194:175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">24670324</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MBio. 2012 Nov 20;3(6):null</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24778221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2016 Mar 3;531(7592):118-21</Citation><ArticleIdList><ArticleId IdType="pubmed">26935699</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Rep. 2018 Jul 10;24(2):441-452</Citation><ArticleIdList><ArticleId IdType="pubmed">29996104</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viruses. 2018 Nov 30;10(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">30513619</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2012 Sep;56(9):4569-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22664969</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2013 Dec 12;18(50):20662</Citation><ArticleIdList><ArticleId IdType="pubmed">24342516</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Opin Ther Targets. 2017 Feb;21(2):131-143</Citation><ArticleIdList><ArticleId IdType="pubmed">27936982</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):216-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27106390</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Yonsei Med J. 2015 Sep;56(5):1174-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26256957</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1985 Jun 14;228(4705):1315-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4001944</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2015 Apr 16;202:151-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25445336</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Front Med. 2017 Dec;11(4):462-470</Citation><ArticleIdList><ArticleId IdType="pubmed">29159596</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2016 Aug;14(8):523-34</Citation><ArticleIdList><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25288733</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2015 Dec;21(12):2186-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26583829</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 May;87(10):5502-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23468491</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2013 Sep 05;18(36):pii=20574</Citation><ArticleIdList><ArticleId IdType="pubmed">24079378</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000415 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000415 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:31544848
|texte= Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:31544848" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |